The Cell Isolation and Transplantation Center (CITC) comprises a state-of-the-art human islet isolation and transplantation laboratory with GMP accreditation, located in the Hospital building, and a basic research laboratory, located in the Faculty of Medicine building. The CITC has established one of the leading programs of clinical human islet transplantation into patients with type 1 diabetes. Since March 1999, it serves as the core facility of the GRAGIL the world’s first multicenter network for clinical islet transplantation including 10 Universities in France. Since 1991 the laboratory has developed an outstanding setup for large-scale human islet isolation. Since 1992, >350 clinical islet transplantations were performed in >250 patients in Geneva and within the GRAGIL centers. Allogeneic transplantations were performed in a variety of indications, i.e. islet transplant alone for “brittle” type 1 diabetes, islet after kidney transplant, and simultaneous islet-kidney transplant for type 1 diabetes patients with end-stage kidney failure. Simultaneous islet-lung or islet-after-lung transplants were also performed in patients with diabetes secondary to cystic fibrosis.
The mission of the our center is to develop innovative therapies for the most severe forms of diabetes. Recently we have established a multi-disciplinary H2020 European consortium with the ambitious goal of developing bioartificial pancreas of high translational potential, with properties of increased functionality and implantability and protection from immune destruction. To achieve our goal we combine advanced tissue engineering strategies, such as 3D organoid generation, hydrogel design, bioartificial organ assembly, and CRISPR-Cas9 gene editing.
The prospective post-doc will contribute to developing an implantable insulin-producing construct suitable for preclinical testing in collaboration with immunologists, endocrinologists and transplant surgeons. More specifically, this individual will be working on islet biology, tissue engineering, biomaterials and regenerative medicine. The candidate will be part of an exciting project in an EU-funded H2020 consortium.
Applicants must have strong organizational and communication skills, be highly self-motivated, and should have a recent Ph.D. degree or M.D./Ph.D. degree in biology, immunology, biochemistry or a related field of biomedical sciences.
Candidates should have hands-on skills with in vitro and in vivo experimental setups and the ability to work independently and as part of a team.
Communication skills with collaborators at different institutions, both verbal and written, including in the English language, are essential.
The candidate will be expected to contribute to experimental design, oral presentations in international meetings and manuscript writing.
Candidates with experience in stem cell and developmental biology, multicolor flow cytometry, confocal microscopy, image acquisition and analysis will be preferred.
Interested applicants should send a cover letter describing their research experience and career goals, along with their CV, list of publications and the names and email addresses of at least three professional references, to email@example.com
What do we offer
- The successful candidate will benefit from a rich and collaborative research environment including the Geneva University School of Medicine and the University Hospitals of Geneva.
- Financial support is available for 5 years, contract will be renewed each year.
- Starting Date: January 1st, 2020.